Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer

Antigens for multi-targeted antibody-guided therapy

Subhash Chauhan, Namita Vinayek, Diane M. Maher, Maria C. Bell, Katrina A. Dunham, Michael D. Koch, Yuhlong Lio, Meena Jaggi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Single antigen-targeted intraperitoneal radioimmunotherapy for ovarian cancer has shown limited success. Due to the heterogeneous expression of tumor antigens on cancer cells, a multi-antigen targeting approach appears logical to augment the therapeutic efficacy of antibody-guided therapy. In the interest of developing this novel approach, ovarian cancer tissue microarray slides containing cancer and benign/non-neoplastic tissue samples (n=92) were processed for single-, double-, and triple-antigen labeling using antibodies for the tumor-associated antigens TAG-72, MUC1, and CA125. Among all ovarian cancer types, 72%, 61 %, and 50% of the samples showed immunolabeling for TAG-72, MUC1, and CA125, respectively. Expression level of these antigens was significantly (p<0.005) higher in advanced stage carcinomas compared with early stage. Of the 48 epithelial ovarian cancer samples, individual anti-TAG-72, MUC1, and CA125 antibody probing showed labeling in 89.5%, 87.5%, and 73.0% of the cases, respectively. In the majority of the cancer samples (>70%), a heterogeneous labeling pattern was observed (only 30-40% of the cancer cells within the sample were labeled). However, upon combining the three antigens (triple-antigen labeling), 98% of the epithelial ovarian cancer samples were labeled and >95% of the cancer cells within each sample were labeled. Our data indicate that the heterogeneous expression of cancer antigens appears to be a major obstacle in antibody-guided therapy, and this can be overcome by multiple antigen targeting. Therapeutic efficacy of antibody-guided therapy for ovarian cancer treatment will be enhanced by the combined targeting of TAG-72, MUC1, and CA125.

Original languageEnglish (US)
Pages (from-to)867-875
Number of pages9
JournalJournal of Histochemistry and Cytochemistry
Volume55
Issue number8
DOIs
StatePublished - Aug 1 2007

Fingerprint

Ovarian Neoplasms
Staining and Labeling
Antigens
Antibodies
Therapeutics
Neoplasms
Radioimmunotherapy
tumor-associated antigen 72
Neoplasm Antigens

All Science Journal Classification (ASJC) codes

  • Anatomy
  • Histology

Cite this

Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer : Antigens for multi-targeted antibody-guided therapy. / Chauhan, Subhash; Vinayek, Namita; Maher, Diane M.; Bell, Maria C.; Dunham, Katrina A.; Koch, Michael D.; Lio, Yuhlong; Jaggi, Meena.

In: Journal of Histochemistry and Cytochemistry, Vol. 55, No. 8, 01.08.2007, p. 867-875.

Research output: Contribution to journalArticle

Chauhan, Subhash ; Vinayek, Namita ; Maher, Diane M. ; Bell, Maria C. ; Dunham, Katrina A. ; Koch, Michael D. ; Lio, Yuhlong ; Jaggi, Meena. / Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer : Antigens for multi-targeted antibody-guided therapy. In: Journal of Histochemistry and Cytochemistry. 2007 ; Vol. 55, No. 8. pp. 867-875.
@article{3b16ddf24f8b4582bfb3fe77e7c53de1,
title = "Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: Antigens for multi-targeted antibody-guided therapy",
abstract = "Single antigen-targeted intraperitoneal radioimmunotherapy for ovarian cancer has shown limited success. Due to the heterogeneous expression of tumor antigens on cancer cells, a multi-antigen targeting approach appears logical to augment the therapeutic efficacy of antibody-guided therapy. In the interest of developing this novel approach, ovarian cancer tissue microarray slides containing cancer and benign/non-neoplastic tissue samples (n=92) were processed for single-, double-, and triple-antigen labeling using antibodies for the tumor-associated antigens TAG-72, MUC1, and CA125. Among all ovarian cancer types, 72{\%}, 61 {\%}, and 50{\%} of the samples showed immunolabeling for TAG-72, MUC1, and CA125, respectively. Expression level of these antigens was significantly (p<0.005) higher in advanced stage carcinomas compared with early stage. Of the 48 epithelial ovarian cancer samples, individual anti-TAG-72, MUC1, and CA125 antibody probing showed labeling in 89.5{\%}, 87.5{\%}, and 73.0{\%} of the cases, respectively. In the majority of the cancer samples (>70{\%}), a heterogeneous labeling pattern was observed (only 30-40{\%} of the cancer cells within the sample were labeled). However, upon combining the three antigens (triple-antigen labeling), 98{\%} of the epithelial ovarian cancer samples were labeled and >95{\%} of the cancer cells within each sample were labeled. Our data indicate that the heterogeneous expression of cancer antigens appears to be a major obstacle in antibody-guided therapy, and this can be overcome by multiple antigen targeting. Therapeutic efficacy of antibody-guided therapy for ovarian cancer treatment will be enhanced by the combined targeting of TAG-72, MUC1, and CA125.",
author = "Subhash Chauhan and Namita Vinayek and Maher, {Diane M.} and Bell, {Maria C.} and Dunham, {Katrina A.} and Koch, {Michael D.} and Yuhlong Lio and Meena Jaggi",
year = "2007",
month = "8",
day = "1",
doi = "10.1369/jhc.7A7213.2007",
language = "English (US)",
volume = "55",
pages = "867--875",
journal = "Journal of Histochemistry and Cytochemistry",
issn = "0022-1554",
publisher = "Histochemical Society Inc.",
number = "8",

}

TY - JOUR

T1 - Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer

T2 - Antigens for multi-targeted antibody-guided therapy

AU - Chauhan, Subhash

AU - Vinayek, Namita

AU - Maher, Diane M.

AU - Bell, Maria C.

AU - Dunham, Katrina A.

AU - Koch, Michael D.

AU - Lio, Yuhlong

AU - Jaggi, Meena

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Single antigen-targeted intraperitoneal radioimmunotherapy for ovarian cancer has shown limited success. Due to the heterogeneous expression of tumor antigens on cancer cells, a multi-antigen targeting approach appears logical to augment the therapeutic efficacy of antibody-guided therapy. In the interest of developing this novel approach, ovarian cancer tissue microarray slides containing cancer and benign/non-neoplastic tissue samples (n=92) were processed for single-, double-, and triple-antigen labeling using antibodies for the tumor-associated antigens TAG-72, MUC1, and CA125. Among all ovarian cancer types, 72%, 61 %, and 50% of the samples showed immunolabeling for TAG-72, MUC1, and CA125, respectively. Expression level of these antigens was significantly (p<0.005) higher in advanced stage carcinomas compared with early stage. Of the 48 epithelial ovarian cancer samples, individual anti-TAG-72, MUC1, and CA125 antibody probing showed labeling in 89.5%, 87.5%, and 73.0% of the cases, respectively. In the majority of the cancer samples (>70%), a heterogeneous labeling pattern was observed (only 30-40% of the cancer cells within the sample were labeled). However, upon combining the three antigens (triple-antigen labeling), 98% of the epithelial ovarian cancer samples were labeled and >95% of the cancer cells within each sample were labeled. Our data indicate that the heterogeneous expression of cancer antigens appears to be a major obstacle in antibody-guided therapy, and this can be overcome by multiple antigen targeting. Therapeutic efficacy of antibody-guided therapy for ovarian cancer treatment will be enhanced by the combined targeting of TAG-72, MUC1, and CA125.

AB - Single antigen-targeted intraperitoneal radioimmunotherapy for ovarian cancer has shown limited success. Due to the heterogeneous expression of tumor antigens on cancer cells, a multi-antigen targeting approach appears logical to augment the therapeutic efficacy of antibody-guided therapy. In the interest of developing this novel approach, ovarian cancer tissue microarray slides containing cancer and benign/non-neoplastic tissue samples (n=92) were processed for single-, double-, and triple-antigen labeling using antibodies for the tumor-associated antigens TAG-72, MUC1, and CA125. Among all ovarian cancer types, 72%, 61 %, and 50% of the samples showed immunolabeling for TAG-72, MUC1, and CA125, respectively. Expression level of these antigens was significantly (p<0.005) higher in advanced stage carcinomas compared with early stage. Of the 48 epithelial ovarian cancer samples, individual anti-TAG-72, MUC1, and CA125 antibody probing showed labeling in 89.5%, 87.5%, and 73.0% of the cases, respectively. In the majority of the cancer samples (>70%), a heterogeneous labeling pattern was observed (only 30-40% of the cancer cells within the sample were labeled). However, upon combining the three antigens (triple-antigen labeling), 98% of the epithelial ovarian cancer samples were labeled and >95% of the cancer cells within each sample were labeled. Our data indicate that the heterogeneous expression of cancer antigens appears to be a major obstacle in antibody-guided therapy, and this can be overcome by multiple antigen targeting. Therapeutic efficacy of antibody-guided therapy for ovarian cancer treatment will be enhanced by the combined targeting of TAG-72, MUC1, and CA125.

UR - http://www.scopus.com/inward/record.url?scp=34447530932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447530932&partnerID=8YFLogxK

U2 - 10.1369/jhc.7A7213.2007

DO - 10.1369/jhc.7A7213.2007

M3 - Article

VL - 55

SP - 867

EP - 875

JO - Journal of Histochemistry and Cytochemistry

JF - Journal of Histochemistry and Cytochemistry

SN - 0022-1554

IS - 8

ER -